FDA’s Cardio-Renal AdComm Losing Some Of Its Anticoagulant Experience

04 Jun 2012

Mori Krantz and Sanjay Kaul are rotating off the committee after participating in all three reviews of J&J/Bayer’s Factor Xa inhibitor rivaroxaban, and nearly all of the meetings on novel anti-clotting agents.

The only two members of FDA’s Cardiovascular and Renal Drugs Advisory Committee to participate in all three reviews of Johnson & Johnson/Bayer HealthCare AG’s Factor Xa inhibitor Xarelto (rivaroxaban) are rotating off the panel.

The membership terms for Mori Krantz, University of Colorado, and Sanjay Kaul, Cedars-Sinai Medical Center, expire June 30. The two...